CC BY 4.0 · AIMS Genet 2019; 06(04): 067-069
DOI: 10.3934/genet.2019.4.67

A robust circular RNA-based prognostic signature for postoperative recurrence in stage II/III colon cancer

Ji Ruan
1   State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
› Author Affiliations


circRNA: circular RNA
DFS: disease-free survival
HR: hazard ratio
CI: confidence interval
OS: overall survival

Publication History

Received: 27 September 2019

Accepted: 28 September 2019

Article published online:
31 March 2021

© 2019. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 Ferlay J, Colombet M, Soerjomataram I. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144: 1941-1953
  • 2 Zhang B, Xie S, Yu I. Differential incidence trends of colon and rectal cancers in Hong Kong: An age-period-cohort analysis. Cancer Commun 2018; 38: 42
  • 3 Kim NK, Kim YW, Han YD. et al. Complete mesocolic excision and central vascular ligation for colon cancer: Principle, anatomy, surgical technique, and outcomes. Surg Oncol 2016; 25: 252-262
  • 4 Schmoll HJ, Van Cutsem E, Stein A. et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-2516
  • 5 Chen T, Huang Y, Wang G. Outcome of colon cancer initially presenting as colon perforation and obstruction. World J Surg Oncol 2017; 15: 164
  • 6 Peng J, Zhang R, Zhao Y. et al. Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer. Chin J Cancer 2017; 36: 96
  • 7 Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: Selecting optimal treatments for individual patients. J Clin Oncol 2015; 33: 1787-1796
  • 8 Yan L, Zhang W. Precision medicine becomes reality-tumor type-agnostic therapy. Cancer Commun 2018; 38: 6
  • 9 Wilusz JE, Sharp PA. Molecular biology. A circuitous route to noncoding RNA. Science 2013; 340: 440-441
  • 10 Jeck WR, Sorrentino JA, Wang K. et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. Cold Spring Harbor Lab Press 2013; 19: 141-157
  • 11 Fang L, Du W, Lyu J. et al. Enhanced breast cancer progression by mutant p53 is inhibited by the circular RNA circ-Ccnb1. Cell Death Differ 2018; 25: 2195-2208
  • 12 Yang Q, Du WW, Wu N. et al. A circular RNA promotes tumorigenesis by inducing c-myc nuclear translocation. Cell Death Differ 2017; 24: 1609-1620
  • 13 Zhang M, Zhao K, Xu X. et al. A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. Nature Commun 2018; 9: 4475
  • 14 Meng S, Zhou H, Feng Z. et al. CircRNA: Functions and properties of a novel potential biomarker for cancer. Mol Cancer 2017; 16: 94
  • 15 Ju H, Zhao Q, Wang F. et al. A circRNA signature predicts postoperative recurrence in stage II/III colon cancer. EMBO Mol Med 2019; 2019: e10168